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Abstract
Background: Genetic and biological evidence supports a role for DISC1 across a spectrum of major mental illnesses,
including schizophrenia and bipolar disorder. There is evidence for genetic interplay between variants in DISC1 and in
biologically interacting loci in psychiatric illness. DISC1 also associates with normal variance in behavioral and brain imaging
phenotypes.
Methodology: Here, we analyze public domain datasets and demonstrate correlations between variants in the DISC1
pathway genes and levels of gene expression. Genetic variants of DISC1, NDE1, PDE4B and PDE4D regulate the expression
of cytoskeletal, synaptogenic, neurodevelopmental and sensory perception proteins. Interestingly, these regulated genes
include existing targets for drug development in depression and psychosis.
Conclusions: Our systematic analysis provides further evidence for the relevance of the DISC1 pathway to major mental
illness, identifies additional potential targets for therapeutic intervention and establishes a general strategy to mine public
datasets for insights into disease pathways.
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Introduction
A key challenge for human genomics is to provide insight into
normal physiological processes and pathogenic mechanisms.
There is strong evidence for a major genetic component to
schizophrenia and bipolar disorder, but, with some notable
exceptions, few of the many proposed candidate genes have been
consistently replicated [1,2]. It has been argued that much of the
genetic variance associated with common complex disease and
quantitative trait variance is likely to be regulatory rather than
coding [3]. The combination of high density SNP analysis with
expression profiling provides a means to assess the genome wide
control of gene expression [4]. This approach has been applied
successfully to the analysis of EBV transformed lymphoblastoid
cell lines and of human tissue [4]. Here, we apply the approach
specifically to the DISC1 pathway for additional insight into
genetic mediators of psychosis and related biology.
Studies of DISC1 and its interactors have established this as one
of the most promising pathways underlying psychosis. This
evidence includes a) linkage and association signals across the
DISC locus for multiple psychiatric, cognitive and brain imaging
[5] traits, b) binding of DISC1 to multiple protein partners with
known roles in neurobiology [5] and c) mouse models of Disc1 by
ENU missense mutagenesis [6] or transgenic over-expression [7–
9], which display overlapping neurodevelopmental and behavioral
phenotypes, with abnormal working memory as a core shared
deficit. Of direct relevance to this study is the recent evidence for
genetic interplay between DISC1 variants [10] and observations of
association to psychiatric illness for the DISC1 interactors NDE1,
NDEL1, PDE4B, and PDE4D [11,12](Text S1). Functional
studies of these proteins have shown that they are involved in
cytoskeletal, and nervous system development related functions,
including synaptic plasticity and neuronal migration [5]. Although
psychosis is a brain disorder, DISC1, NDE1, NDEL1, PDE4B and
PDE4D and manyothermembers of theknownDISC1 interactome
are expressed in lymphoblastoid cell lines. We conjectured that a
global analysis of normal variance in gene expression in lympho-
blastoid cells might provide useful self-standing insights into pathway
biology and complement clinically and technically challenging
limitations of comparative post-mortem brain expression studies
[13]. We have therefore mined publicly available expression data
derived from lymphoblastoid cell lines of HapMap individuals for
significant alterations in genome wide gene expression levels,
mediated by genetic variations in the DISC1 pathway. We confirm
the involvement of DISC1, NDE1, PDE4B and PDE4D in
cytoskeletal, synaptogenic and neurodevelopmental functions, and
provide new evidence that this pathway may also play a role in
sensory perception.
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Previous studies have shown that expression levels of full length
DISC1 are reduced by half in lymphoblastoid cell lines derived
from t(1;11) cases [14] and that S704C missense variants alter
binding of NDEL1 [15], arguing that altering either the quality or
the quantity of DISC1 can be pathognomonic But, as yet, there
have been no studies to determine whether the cellular effects of
these alternative genetic mechanisms are fundamentally similar or
distinct. To address this, we devised a data mining and integration
strategy, summarized in Figure 1. First, we examined the effect of
a) six novel variants shown here to exert an effect in cis on DISC1
expression b) three common missense variants R264Q
(rs3738401), L607F (rs6675281) and S704C (rs821616), c) the 3
SNPs, rs1538979, rs821577 and rs821633, reported to show
interplay conferring ‘risk’, ‘neutral’ and ‘protective’ effects on
schizophrenia and bipolar disorder [10] and d) variants previously
reported as associated with schizophrenia or related psychotic
traits in European cohorts for the DISC1 interactors NDE1,
NDEL1, PDE4B and PDE4D.
Novel DISC1 cis-acting variants were identified by testing SNPs
from 10 kb upstream of the immediately adjacent gene TSNAX to
10 kb downstream of DISC1 for association to expression values
of DISC1. Expression values were from four publicly available
data sets (GSE6536 in NCBI GEO) drawn from a common set of
210 lymphoblastoid cell lines from the four HapMap population
cohorts; 60 CEU, 60 YRI, 45 CHB and 45 JPT [16]. Of the 754
variants tested, only one, rs1765778, located 30 kb upstream of
DISC1, displayed significant association in all four populations (p-
value range =0.04920.0094). A further 5 SNPs displayed
significant association (p,0.05) in three of the four populations,
the common exception being the Japanese population. One of
these five SNPs, rs3738398 is located 221 bp upstream of the
DISC1 start site and 75 bp upstream of the CpG island that spans
exon 1 of DISC1, suggesting that these variants may be
representing the as yet undefined promoter region of DISC1. All
six variants locate within the same CEU D9 haplotype block,
which is also the longest haplotype block of the four populations
(Figure S1 and Table S1), and have an average r
2 between them of
0.69, and a maximum r
2 of 0.87 between rs1765778 and
rs1655297. In all six instances, the minor alleles were associated
with decreased DISC1 expression. Carriers of the minor alleles in
the CEU cohort have, on average, a reduction of 14.81% (95%
CI=13.96–15.66) in DISC1 expression, whilst homozygotes of the
minor alleles have on average a 18.97% (95% CI=17.84–20.10)
reduction.
We then tested by ANOVA the genotypes of the three missense
polymorphisms, the three genetic interplay variants (comparing
‘risk’, ‘neutral’ and ‘protective’ genotypes), and the six cis-acting
variants for global effects on gene expression (Table S2). This used
public datasets from three studies that used the CEU population
[16–18], with each study using a different sub-cohort of individuals
and different platform to measure expression levels. Only those
genes that were significantly differentially expressed (p,0.05) and
in the same direction across all array test platforms were
considered for gene ontology analysis (materials and methods &
Table S3). To test for shared effects down-stream of DISC1, the
same global analysis was performed on other members of the
DISC1 pathway for which variants had previously been reported
as associated with schizophrenia or related psychotic traits in
European cohorts. These comprised: for NDE1, 4 SNPs and 1
haplotype; for NDEL1, 1 SNP and 1 haplotype; for PDE4B, 3
SNPs and 2 haplotypes; and for PDE4D, 1 SNP and 1 haplotype
[11,12](Text S1 and Table S2).
Of the total 77154 gene targets represented by all three
platforms, 13145 genes are targeted by more than one experiment.
Figure 1. Flow chart to demonstrate the analysis performed here. This protocol can be adapted to any chosen gene, pathway and disorder
by simply replacing DISC1 with the gene of primary interest.
doi:10.1371/journal.pone.0004906.g001
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in the cross-sample analysis performed (Table S3). Greater than
expected numbers of genes affected were seen for eight of the
fourteen variants tested, three of them significantly greater at the
0.05 level. These were DISC1 rs3738401 (R264Q) (n=47,
p=0.012); NDE1 SNPs rs4781678 (n=39), rs2242549 (n=29),
rs881803 (n=52, p=0.0028); the NDE1 tagging haplotype
(n=36); the PDE4B SNP rs7412571 (n=83, p=0.000000037)
and haplotype (n=31); and the PDE4D haplotype (n=36) (Table
S3).
528 genes (4.02% of all targets represented on multiple array
platforms) were differentially expressed across all variants tested
(Table S3). Of these, 17 genes (3.21%) were influenced by variants
in more than one DISC1 pathway gene. Of the total 178 genes
identified by all DISC1 variants, 11 (6.17%) were also identified by
variants in the other DISC1 pathway genes. Expression of TUBB3
was uniquely affected by both regulatory and missense DISC1
variants. 35 of the 528 genes (6.63%) have pre-existing supporting
evidence for a role in psychosis. Seven genes, ATF7IP, BCR,
CLU, DYNLL1, FEZ1, SNAP91 and SYN2, are interactors of
DISC1 or the extended DISC1 pathway [19]. Seven genes, APP
[20], ERBB3 [20], FEZ1 [21], HSPA2 [20], SERPINI1 [20],
SOX10 [21] and SYN2 [22], display altered expression in studies
of schizophrenia or bipolar disorder. Six genes, CLOCK [23],
FEZ1, GRIA3, NOTCH4, SYN2, and TACR1, have been
reported associated with schizophrenia (www.schizophreniaforum.
org/res/sczgene/default.asp; [2]) or bipolar disorder. Fifteen
genes, ALKBH4 [24], BCR [25], CD160 [26], DAZ3 [24],
GJA5 [24,25], IL9R [24], KIF13A [26], MGLL [25], NLGN4Y
[24], PRKY [24], RGS12 [26], SCHIP1 [25], USP7 [25], VCY
[24] and ZNF140 [25], are subject to copy number variation in
individuals with schizophrenia. Further, the Ingenuity Pathway
Analysis (IngenuityH Systems, www.ingenuity.com) database
identifies 139 genes as being targets for drugs for psychiatric
illness. Of these 139, the expression of seven genes (5%), namely
CA12, CHRNA5, GRIA3, HTR3A, SCN9A, TUBB3 and
TUBD1 were altered by the presence of DISC1 pathway variants
(number expected by chance to be observed on multiple platforms
and be a known drug target=0.29; p=0.0074 (Table 1). Only the
DISC1 variant rs3738401 (R264Q) affected more than one of
these target genes, significantly altering the expression levels of
CHRNA5, TUBB3 and TUBD1. Ingenuity Pathway Analysis
(IngenuityH Systems, www.ingenuity.com) also enabled additional
exploration of how the identified genes relate to DISC1 and the
DISC1 pathway. Using the build function and connecting the 528
genes to the core DISC1 interactome, only allowing for direct
interaction, 100 (18.94%) genes can be generated into a network
(Figure 2) with relationships supported by at least 1 reference from
the literature, from a textbook, or from canonical information
stored in the Ingenuity knowledge base.
To determine whether these 10 DISC1 and 14 DISC1 pathway
variants identified convergent biological pathways, the gene
ontology (GO) tree machine [27] was used to test for over
abundance of similar functions (Table S4). GO term searches were
performed on gene sets identified by a) individual variants that
exceeded the expectation level, b) multiple variants in linkage
disequilibrium with each other (that is all DISC1 ‘cis’ variants, and
all NDE1 variants) and c) variants in different DISC1 pathway
genes (all major mental illness associated variants, and all variants).
Significant enrichment was observed for: cytoskeletal functions
(DISC1, rs3738401 (p-value range, 0.004720.00039) and NDE1,
haplotype (p-value range, 0.006020.0010)), synaptogenesis
(PDE4B, rs7412571 (p-value=0.0035)), transcription factor activ-
ity (DISC1, rs3738401 (p-value=0.010) PDE4B rs7412571 (p-
value range, 0.005320.0048)) and sensory perception (NDE1,
rs881803 (p-value=0.0038). Cytoskeletal functions and synapto-
genesis have already been identified as functions of the DISC1
pathway [5]. Cytoskeletal functions were also highlighted with
DISC1 ‘cis’ variants, ‘all DISC1 pathway variants’ and ‘all
associated variants’. Nervous system development is also a
predicted function of the DISC1 pathway [5] and was affected
here by the PDE4B haplotype comprising rs2503166, rs583018
and rs526772 (p-value=0.0014). Additionally, the gene lists for
the DISC1 ‘cis’ variants, rs6541280 and rs823167, were also
enriched for sensory perception gene ontology terms despite
affecting fewer genes than would be expected by chance. When
genes identified by associating variants in more than one DISC1
pathway member were considered, there was a significant over
representation of genes involved in cytoskeleton organization and
biogenesis. When all DISC1 missense and regulatory variants were
added to the analysis, GO term enrichment was observed for
neurotransmitter receptor activity and in G-protein coupled
peptide receptor activity (Table 2, Figure S2 and Table S4). Our
analysis also supports previous suggestions [10,28] that mutations
affecting either the quality or quantity of DISC1 may have subtly
different phenotypic and pathogenic consequences.
Discussion
Our study has highlighted the role of six DISC1 cis-variants in
significantly altering the expression levels of the DISC1 gene in a
semi-dominant fashion (15% average reduction in heterozygotes
versus 19% in homozygotes). The reductions of DISC1 gene
expression levels, although modest, may, through the hub function
Table 1. Psychiatric drug target genes that display DISC1 pathway mediated differential expression.
Target Gene function Mediating Variant Treated Disorder Drug Action
CA12 Zinc metalloenzyme NDE1 Haplotype Bipolar Disorder Topiramate Inhibitor
SCN9A Sodium channel subunit PDE4B (rs7412571) Bipolar Disorder and Depression Riluzole Blocker
GRIA3 Glutamate receptor NDE1 (rs2242549) Depression ORG24448 Modulator
HTR3A Serotonin receptor NDE1 (rs4781678) Schizophrenia Memantine Antagonist
Depression and Anxiety Mirtazapine Antagonist
CHRNA5 Cholinergic receptor DISC1 (rs823167, rs3738401, rs821616) Psychosis and ADHD ABT-089 Agonist
TUBB3 Neural microtubule dynamics DISC1 (rs1025526, rs6541280, rs3738401) Schizophrenia AL 108 Binder
TUBD1 Centrosomal DISC1 (rs1025526, rs6541280, rs3738401) Schizophrenia AL 108 Binder
doi:10.1371/journal.pone.0004906.t001
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tally and physiologically relevant, effects.
Further, our analysis has added to the evidence for the DISC1
pathway having a role in the regulation of cytoskeletal function,
synaptogenesis, and neurodevelopment [5] and sensory percep-
tion. This evidence pertains to normal variance in gene expression,
but may also be clinically relevant and could be tested by
association studies of target genes and expression studies of post-
mortem brain tissue. Intriguingly, ‘cAMP mediated signaling’
appears as an overrepresented term for the NDE1 variant
rs4781678 (Table S4) and not, as might have been expected, for
a PDE4B or PDE4D variant. We have however recently
demonstrated that DISC1, PDE4 and NDE1 co-associate and
co-localize at the synapse, suggesting a role for NDE1 in co-
modulating PDE4 dependent cAMP levels [29]. Sensory percep-
tion is a novel, emergent finding that fits well with the underlying
concepts in psychosis of altered perception and salience [30]. This
finding provides a new avenue for experimentation, for example in
the analysis of mice mutant for Disc1 pathway genes [6–9].
The identification of seven psychoactive drug targets is
noteworthy. To the best of our knowledge, these were identified
and developed without any prior knowledge of a biological link to
the DISC1 pathway per se. We argue from this that the DISC1
pathway offers a valid and circumscribed target for additional drug
target development. Moreover and importantly, our analysis
suggests that DISC1 pathway variant profiling may serve as a
useful predictor of individual response to a given therapeutic.
The approach we have taken (Figure 1) can be adapted to any
chosen gene or pathway. We suggest that this may prove a useful
strategy for independent evaluation of candidate genes, their likely
contribution to disease variance, their potential utility as
therapeutic targets and as predictors of response to treatment.
Materials and Methods
Multiple publicly available data sets were used to test the effects
of genetic variants on genome-wide gene expression levels.
Genotype and phased haplotype data were collected from the
HapMap project ([31]; www.hapmap.org/), whilst expression data
were collected from the NCBI Gene Expression Omnibus (GEO)
database (www.ncbi.nlm.nih.gov/geo/ ) for studies that have used
lymphoblastoid cell lines, where the individuals used partially or
completely overlapped with the individuals included in the
HapMap project.
Expression data
The expression data came from three independent laboratories
and can be obtained from the NCBI GEO database under the
following identification codes: GDS2106 [17], GDS1048 [18], and
GSE6536 [16]. One group had performed a replication analysis
for their samples (GDS2106), which we used here as a fourth
comparator being a technical replicate for the observations in
GDS2106. Data were derived from different gene chip platforms:
GDS2106 used Affymetrix GeneChip Human HG-Focus Target
Figure 2. Network of how 100 of the 528 genes identified with significant differential expression relate to DISC1and its core
interactors. Network generated through the use of Ingenuity Pathway Analysis (Ingenuity SystemsH, www.ingenuity.com), using the build function
and connecting the identified genes to the core DISC1 interactome, only allowing for direct interaction. Relationships are supported by at least 1
reference from the literature, from a textbook, or from canonical information stored in the Ingenuity knowledge base.
doi:10.1371/journal.pone.0004906.g002
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Illumina Sentrix Human-6 Expression BeadChip. The Affymetrix
platform was re-annotated using a custom GeneChip library file
(CDF file) [32]. Each study tested a different and partially
overlapping sub-set of the CEU individuals (Figure S3).
Statistical analysis
All variants considered to be ‘cis’ to the DISC1 gene (HapMap
Build 35 co-ordinates, Chr1:227961133..228493750, 10 kb up-
stream of the immediately adjacent gene TSNAX to 10 kb
downstream of DISC1) were tested for association to variance in
the expression levels of DISC1 using the one-way ANOVA
function in SPSS (version 14.0 for Windows). This was performed
for all four HapMap populations using the expression data from
the GEO dataset GSE6536. It was predicted that if a genomic area
truly regulates DISC1 expression, then that region would be
detected to associate in all populations. These findings were
mapped back on to the linkage disequilibrium (LD) structure of
this region. The pattern of LD was defined using the solid spine of
LD (D9.0.8) to form haplotype blocks. Neighboring haplotype
blocks with a Hedrick’s multiallelic D9.0.9 [33] were joined to
form one haplotype block.
Tests for association between genetic variants and gene
expression were performed using the MA-ANOVA program in
R, for each variant (n=24) on each platform (n=4, total of 96
genome wide analyses). The datasets ranged from 24 to 60
individuals analyzed. To take account of these multiple tests and
between study variables, only those genes that displayed significant
differences in expression (p,0.05) in all datasets on which it was
measured and which changed in the same direction were
considered robust and taken forward. This produced a list of
genes that were differentially expressed for each DISC1 pathway
variant. To determine whether the number of genes observed was
greater than that expected by chance we calculated how many
genes would be expected to show affected expression using a the
5% level for each platform. Since we were only looking for genes
Table 2. Table of significant gene ontology terms that are biologically relevant to the DISC1 pathway or major mental illness.
Variant Gene Number Gene Ontology Term p-value Proteins Involved
DISC1 rs1025526 19 peptide receptor activity 0.0091 TUBB3; FPR1
peptide receptor activity\, G-protein coupled 0.0091 TUBB3; FPR1
DISC1 rs6541280 19 sensory perception of mechanical stimulus 0.0093 WFS1; CD151
sensory perception of sound 0.0093 WFS1; CD151
DISC1 rs823167 19 sensory perception of mechanical stimulus 0.0093 WFS1; CD151
sensory perception of sound 0.0093 WFS1; CD151
DISC1 rs3738401 47 microtubule organizing center 0.00077 PPP4R2; MLF1; TUBD1
centrosome 0.00049 PPP4R2; MLF1; TUBD1
microtubule cytoskeleton 0.0049 TUBB3; PPP4R2; MLF1; TUBD1
NDE1 Haplotype 36 actin cytoskeleton organization and biogenesis 0.0076 AVIL; EPB41; ARHGAP6
actin cytoskeleton 0.0027 AVIL; DAG1; EPB41; ARHGAP6
NDE1 rs881803 52 sensory perception of mechanical stimulus 0.0085 TRIOBP; GJB3; SOX10
sensory perception of sound 0.0085 TRIOBP; GJB3; SOX10
PDE4B Haplotype* 4 system development 0.0025 DRP2; GAS7
nervous system development 0.0024 DRP2; GAS7
PDE4B rs7412571 83 synapse organization and biogenesis 0.0067 PCDHB13; PCDHB2
synaptogenesis 0.0067 PCDHB13; PCDHB2
DISC1 cis 20 sensory perception of light stimulus 0.0021 OCLM; WFS1; CD151
visual perception 0.0021 OCLM; WFS1; CD151
Associated Variants 5 organelle organization and biogenesis 0.0051 LIMA1; SMC1A
cytoskeleton organization and biogenesis 0.0010 LIMA1; SMC1A
All Variants 17 organelle organization and biogenesis 0.0057 TUBB3; TIMM8A; LIMA1; SMC1A
cytoskeleton organization and biogenesis 0.0044 TUBB3; LIMA1; SMC1A
microtubule-based process 0.0059 TUBB3; SMC1A
neurotransmitter binding 0.0045 CHRNA5; TACR1
neurotransmitter receptor activity 0.0041 CHRNA5; TACR1
peptide receptor activity 0.0065 TUBB3; TACR1
peptide receptor activity\, G-protein coupled 0.0065 TUBB3; TACR1
transmembrane receptor activity 0.0064 TUBB3; CHRNA5; P2RY10; TACR1
G-protein coupled receptor activity 0.0068 TUBB3; P2RY10; TACR1
rhodopsin-like receptor activity 0.0037 TUBB3; P2RY10; TACR1
cytoskeletal part 0.0081 TUBB3; PPP4R2; LIMA1
*Haplotype of SNPs rs2503166, rs583018 and rs526772.
doi:10.1371/journal.pone.0004906.t002
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(0.0560.05) for genes on two platforms (10249 genes:
0.0560.05610249=25.62), an expected level of 0.0125%
(0.0560.0560.05) for genes on three platforms (545 genes:
0.0560.0560.056545=0.068) and an expected level of
0.000625% (0.0560.0560.0560.05) for genes on four platforms
(2351 genes: 0.0560.0560.0560.0562351=0.015). This resulted
in an expected value of 25.71 genes identified per variant.
Gene Ontology Analysis
The list of genes differentially expressed for each variant was
uploaded into the web based Gene Ontology Tree Machine ([27];
http://bioinfo.vanderbilt.edu/gotm/ ) and the hypergeometric
test utilized by GOTM to test for over representation of genes of
similar function. GOTM tests were also applied to gene lists
identified by more than one variant within the following
categories, a) DISC1 expression altering variants, b) NDE1
variants, c) all variants that associate with major mental illness,
d) all variants from the DISC1 pathway. The list of observed
differentially expressed genes was compared to a reference gene
list of all genes that had targets on multiple platforms, to determine
if there was significant enrichment of gene ontology terms. The
GOTM website is updated periodically and can not be searched
using prior data assemblies. The analysis performed here was on
the data assembly as it stood on 8th May 2008.
Supporting Information
Figure S1 Illustration from the UCSC genome browser to show
the locations of the DISC1 cis SNPs tested for association to
DISC1 expression in relation to the LD structure in the four
populations, the location of the DISC1 coding sequence and
potential regulatory elements. Track 1, shows UCSC chromo-
somal location from the March 2006 build. Track 2 shows the
chromosomal band. Track 3 shows the location of DISC1. Tracks
4, 6, 8 and 10 show the LD block structure in the four populations
(alternating colors are for clarity). Tracks 5, 7, 9 and 11 show the
SNPs used in the analysis and whether they associated below the
0.05 level of significance (Black SNPs are significant at the 0.05
level, Grey SNPs are not). Tracks 12 to 14 show the locations of
potential regulatory elements in this region. a) Whole region
analyzed. b) Close up of the 59 end of DISC1 where consistent
significant findings were observed.
Found at: doi:10.1371/journal.pone.0004906.s001 (2.69 MB TIF)
Figure S2 Gene ontology tree illustrations, parts a) to w), from the
Gene Ontology Tree Machine ([1]; http://bioinfo.vanderbilt.edu/
gotm/ ) for the genes identified to be significantly differentially
expressed by each variant and the four variant groupings used in this
study. Ontological functions illustrated in red are significantly over
represented in the genes whose expression levels are altered by that
variant. a) DISC1 rs1765778 b) DISC1 rs1025526 c) DISC1
rs6541280 d) DISC1 rs3738398 e) DISC1 rs823167 f) DISC1
rs3738401 g) DISC1 rs821616 h) DISC1 interplay model i) NDE1
rs4781678 j) NDE1 rs2242549 k) NDE1 rs881803 l) NDE1
rs2075512 m) NDE1 haplotype n) NDEL1 haplotype o) PDE4B
haplotype (Haplotype of rs4503327, rs2503222 and rs6588186) p)
PDE4B rs7412571 q) PDE4B Haplotype (Haplotype of rs2503166,
rs583018 and rs526772) r) PDE4B rs2503177 s) PDE4D rs1120303
t) DISC1 overlapping genes for DISC1 expression altering variants
u) NDE1 overlapping genes v) DISC1 pathway associating variants
overlapping genesw)DISC1 pathway allvariantsoverlapping genes.
1.RZhang B, Schmoyer D, Kirov S, Snoddy J (2004) GOTree
Machine (GOTM): a web-based platform for interpreting sets of
interesting genes using Gene Ontology hierarchies. BMC Bioinfor-
matics 5: 16.
Found at: doi:10.1371/journal.pone.0004906.s002 (10.22 MB
TIF)
Figure S3 Venn diagram of the numbers of overlapping CEU
individuals in the three publicly available expression datasets.
Found at: doi:10.1371/journal.pone.0004906.s003 (1.48 MB TIF)
Table S1 Table to show the association between cis variants of
DISC1 and DISC1 gene expression in the four HapMap
populations. P-values in bold are below 0.05.
Found at: doi:10.1371/journal.pone.0004906.s004 (0.12 MB
XLS)
Table S2 Variants from the DISC1 pathway used in analysis of
correlations with global gene expression levels.
Found at: doi:10.1371/journal.pone.0004906.s005 (0.02 MB
XLS)
Table S3 Table to show the number of genes significantly
altered by each variant and the direction and fold change of effect
for each gene.
Found at: doi:10.1371/journal.pone.0004906.s006 (0.18 MB
XLS)
Table S4 Table to show the gene ontology terms that are
significantly enriched in the gene lists for each variant and the four
groupings of variants.
Found at: doi:10.1371/journal.pone.0004906.s007 (0.03 MB
XLS)
Text S1 Unpublished article. Tomppo L, Hennah W, Lahermo
P, Loukola A, Tuulio-Henriksson A, et al. (2009) Genes of the
DISC1 Pathways in the Etiology of Schizophrenia. Biol Psychi-
atry: (in press)
Found at: doi:10.1371/journal.pone.0004906.s008 (0.81 MB
PDF)
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